Medicine and Dentistry
Cystectomy
100%
Muscle Invasive Bladder Cancer
89%
Bladder Cancer
80%
Transitional Cell Carcinoma
67%
Non Muscle Invasive Bladder Cancer
55%
Bladder
53%
Neoadjuvant Chemotherapy
48%
Neoplasm
34%
Overall Survival
31%
Recurrent Disease
29%
Diseases
24%
Urothelial Cancer
24%
Lymph Node
23%
Nephroureterectomy
22%
Chemoradiotherapy
19%
Upper Urinary Tract
19%
Clinical Trial
18%
Biological Marker
18%
Quality of Life
16%
Radiation Therapy
16%
Recurrence Free Survival
15%
Cohort Analysis
15%
Urology
14%
Metastatic Carcinoma
13%
Mycobacterium Bovis BCG
13%
Arm
13%
Disease Specific Survival
13%
Systemic Therapy
12%
Disease Free Survival
12%
Surgical Margin
12%
Cisplatin
12%
Cancer Registry
12%
Urinary Tract
11%
Radical Surgery
10%
Retroperitoneal Lymph Node Dissection
10%
Lower Urinary Tract Symptom
10%
Systematic Review
9%
Carcinoma in Situ
9%
Lymph Node Metastasis
9%
Progression Free Survival
9%
Monotherapy
9%
Prospective Cohort Study
9%
Pembrolizumab
9%
Hazard Ratio
8%
Cancer Specific Survival
8%
Pelvis
8%
Effectiveness Study
8%
Bladder Outlet Obstruction
8%
Testis Cancer
8%
Programmed Death 1 Ligand 1
8%
Pharmacology, Toxicology and Pharmaceutical Science
Non Muscle Invasive Bladder Cancer
48%
Bladder Cancer
48%
Chemotherapy
37%
Muscle Invasive Bladder Cancer
32%
Transitional Cell Carcinoma
25%
Recurrent Disease
22%
Neoplasm
19%
Mycobacterium Bovis BCG
19%
Overall Survival
16%
Chemoradiation Therapy
15%
Cohort Study
14%
Bladder Obstruction
13%
Disease Specific Survival
12%
Disease Free Survival
12%
Diseases
11%
Pembrolizumab
10%
Obstruction
10%
Lower Urinary Tract Symptom
10%
Malignant Neoplasm
9%
Cancer Registry
9%
Adverse Event
9%
Monotherapy
8%
Programmed Death 1 Ligand 1
8%
Prospective Cohort Study
8%
Carcinoma in Situ
7%
Immunotherapy
7%
Biological Marker
7%
Cisplatin
6%
Prostate Cancer
6%
Lymph Node Metastasis
6%
Carboplatin
6%
Survival Rate
5%